Clinical Report: Spectrum Killian, National Dentex Labs and Open Implants Unite Under SPEKTRA

Overview

Spectrum Killian, National Dentex Labs (NDX), and Open Implants announced their combination under SPEKTRA, a parent company spanning dental laboratory services, digital manufacturing, and implant component production. The companies say they intend to integrate technology, manufacturing, and clinical support through digital workflows for restorative dentistry; the announcement does not report clinical outcome data.

Background

Digital dentistry involves connected clinical tools, materials, manufacturing processes, and support systems. The announcement describes these elements as fragmented and says practices are increasingly incorporating intraoral scanning and chairside workflows. Spectrum Killian contributes manufacturing processes and California Centers of Excellence, NDX contributes an international laboratory network and manufacturing infrastructure, and Open Implants contributes implant component manufacturing. Separately, the European Federation of Periodontology’s 2023 guideline addresses prevention and management of peri-implant diseases, while a four-year randomized trial has compared digital and conventional workflows for single implant-supported zirconia crowns.

Data Highlights

The SPEKTRA announcement provides no numerical or clinical trial data. It describes the organizations’ capabilities and stated plans for integrated digital workflows.

Key Findings

• SPEKTRA brings together Spectrum Killian, NDX, and Open Implants under a new parent company.
• The combined organization spans dental laboratory services, digital manufacturing, and implant component production.
• Spectrum Killian operates California Centers of Excellence using documented, repeatable restorative manufacturing processes.
• NDX contributes an international network of local dental laboratories, manufacturing infrastructure, and relationships with dental practices.
• Open Implants is described in the announcement as an FDA-registered manufacturer of implant components.
• The companies state that SPEKTRA will develop manufacturing processes and digital workflows intended to support consistent restorative production and clinical support; no clinical effectiveness results are reported.

Clinical Implications

The announcement describes an organizational effort to connect laboratory, manufacturing, and clinical support functions as practices adopt intraoral scanning and chairside workflows. It does not provide evidence that the combination or its planned workflows improve clinical outcomes.

Conclusion

SPEKTRA combines three organizations with complementary laboratory, manufacturing, and implant component capabilities. Its stated focus is integrated digital workflows, with clinical effects not established in the announcement.

Related Resources & Content

1. European Federation of Periodontology, Clinical Guideline, 2023 -- Prevention and treatment of peri-implant diseases
2. Clinical and Radiographic Outcomes of Single Implant-Supported Zirconia Crowns Following a Digital and Conventional Workflow: Four-Year Follow-Up of a Randomized Controlled Clinical Trial, 2024
3. inside dentistry, 2023 -- DEXIS™ IOS, DTX Studio™ Clinic and SprintRay™ Announce Strategic Integration and Commercial Collaboration to Streamline Digital Dental Workflow
4. inside dental technology — DENTSPLY Acquires Astra Tech
5. compendium — S.P.E.C. 3® LED: COLTENE’s Response to Dentistry’s Curing Needs
6. inside dentistry — Spectra™ - An Innovation in Caries Detection
7. EFP Clinical Guideline
8. Clinical and Radiographic Outcomes of Single Implant-Supported Zirconia Crowns Following a Digital and Conventional Workflow: Four-Year Follow-Up of a Randomized Controlled Clinical Trial
9. DEXIS™ IOS, DTX Studio™ Clinic and SprintRay™ Announce Strategic Integration and Commercial Collaboration to Streamline Digital Dental Workflow
10. Are monolithic zirconia complete arch implant-supported prostheses reliable? A systematic review and meta-analysis - PubMed